Salud financiera de hoja de balance de Sinopharm Group
Salud financiera controles de criterios 6/6
Sinopharm Group tiene un patrimonio de accionistas total de CN¥120.3B y una deuda total de CN¥68.6B, lo que sitúa su ratio deuda-patrimonio en 57%. Sus activos y pasivos totales son CN¥383.4B y CN¥263.1B respectivamente. El BAIT de Sinopharm Group es de CN¥22.3B, por lo que su ratio de cobertura de intereses es de 10.3. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥63.8B.
Información clave
57.0%
Ratio deuda-patrimonio
CN¥68.56b
Deuda
| Ratio de cobertura de intereses | 10.3x |
| Efectivo | CN¥67.14b |
| Patrimonio | CN¥120.32b |
| Total pasivo | CN¥263.08b |
| Activos totales | CN¥383.39b |
Actualizaciones recientes sobre salud financiera
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Recent updates
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?
Jan 06What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?
Dec 25Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares
Dec 15We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Dec 04Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years
Nov 25Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CN¥336.8B) de 1099 superan a sus pasivos a corto plazo (CN¥241.5B).
Pasivo a largo plazo: Los activos a corto plazo de 1099 (CN¥336.8B) superan a sus pasivos a largo plazo (CN¥21.6B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (4%) de 1099 se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de 1099 ha pasado de 80.6% a 57% en los últimos 5 años.
Cobertura de la deuda: La deuda de 1099 está bien cubierta por el flujo de caja operativo (25%).
Cobertura de intereses: Los pagos de intereses de la deuda de 1099 están bien cubiertos por el BAIT (10.3x cobertura).